Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical...
Staff
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board
Figure: 1 Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board Carlsbad, CA, Dec. 17, 2024 (GLOBE...
BrightInsight Expands Global Digital Partnership with Sanofi to Build Drug Companion Apps for its Major Specialty Therapies
Following the success of the MyWay app in the US and Germany, the partners will expand brand-oriented digital health companion...
TOMI Environmental Solutions Expands Presence in Canadian Market Through Enhanced Partnership with Betatek, Inc.
FREDERICK, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in...
NeuroOne® Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025
Company’s Exclusive Distribution Agreement with Zimmer Biomet included $3.0 Million Upfront Payment: Expected to Drive Revenue and Expand Margins Significantly...
Gelteq Receives FDA Approval of its Suitability Petition for New Animal Drug
Approval grants Gelteq fast track pathway for drug and entrance into the animal pharmaceuticals spaceNEW YORK, Dec. 17, 2024 (GLOBE...
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors
LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical...
December 2024 Letter to Shareholders
VANCOUVER, Washington, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, As I look back on 2024, during which CytoDyn Inc....
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year Survival Rate...
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol...
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
Cyclerion Has Renegotiated Praliciguat License Agreement to Obtain Upfront and Near-Term Payments as well as Entered into a License Option...
Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025
TAMPA, FL, Dec. 17, 2024 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (the “Company”) (NASDAQ: SCNX), a specialty pharma company with...
Avalyn to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled...
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional safety data and...
Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia
FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review...
Transpire Bio Achieves Important Corporate Milestone with Completion of First Human Subject Study in the Company’s Asthma and Chronic Obstructive Pulmonary Disease Inhaled Drug Program
WESTON, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated, clinical-stage biopharmaceutical company focused on developing inhaled medicines,...
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
- The company will provide additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer -...
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in...
Upstream Bio Appoints Allison Ambrose as General Counsel
WALTHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory...
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year Survival Rate...